<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01878188</url>
  </required_header>
  <id_info>
    <org_study_id>BC-BLAD-01</org_study_id>
    <nct_id>NCT01878188</nct_id>
  </id_info>
  <brief_title>Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma</brief_title>
  <official_title>Phase I Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anchiano Therapeutics Israel Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anchiano Therapeutics Israel Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Safety and tolerability of three regimens of intravesically administered BC-819/PEI and
           BCG (number of participants with AEs, discontinuations due to AEs)

        -  Recurrence after treatment with BC-819/PEI and BCG

        -  Approximately 38 patients with superficial transitional cell carcinoma TCC) of the
           bladder

        -  After initial evaluation and qualification, patients will be randomized to one of three
           treatment groups, either alternating, sequential or twice weekly
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of three regimens of intravesically administered BC-819/PEI and BCG by number of subjects with AEs and change from baseline for clinical safety laboratory tests</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence of bladder cancer after treatment with BC-819/PEI and BCG</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Transitional Cell Carcinoma of Bladder</condition>
  <arm_group>
    <arm_group_label>BC-819/PEI and BCG alternating</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 or 6 weekly treatments of BC-819/PEI alternating with 6 treatments of BCG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BC-819/PEI and BCG Vaccine sequential</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 weekly treatments of BC-819/PEI followed by 6 weekly treatments of BCG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>twice-weekly treatments of BC-819 and BCG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 twice-weekly treatments of BC-819/PEI and BCG</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BC-819/PEI</intervention_name>
    <description>Intravesical instillation</description>
    <arm_group_label>BC-819/PEI and BCG Vaccine sequential</arm_group_label>
    <arm_group_label>BC-819/PEI and BCG alternating</arm_group_label>
    <arm_group_label>twice-weekly treatments of BC-819 and BCG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCG Vaccine</intervention_name>
    <description>intravesical instillations</description>
    <arm_group_label>BC-819/PEI and BCG Vaccine sequential</arm_group_label>
    <arm_group_label>BC-819/PEI and BCG alternating</arm_group_label>
    <arm_group_label>twice-weekly treatments of BC-819 and BCG</arm_group_label>
    <other_name>OncoTICE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with superficial papillary transitional cell carcinoma of the bladder for
             whom BCG is clinically indicated. If CIS is present, diagnosis needs to be confirmed
             by biopsy prior to the start of the study.

          2. Males or females more than 18 years old

          3. All papillary tumors must be resected within 8 weeks prior to the start of study
             therapy.

          4. ECOG performance status 2 or less.

          5. Adequate hematologic function, as demonstrated by

               1. Hemoglobin 10 g/dL or higher

               2. ANC 1.5 x 109/L or higher

               3. Platelets higher than 100 x 109/L

          6. Adequate liver and renal function as demonstrated by

               1. AST and ALT each 3.0 x ULN or less

               2. Total bilirubin 1.5 x ULN or less

               3. Creatinine 1.5 X ULN OR less, creatinine clearance &gt;60 mL/min

          7. If fertile and sexually active, must use adequate contraception

          8. Must be able to comply with protocol requirements, including attendance at required
             clinic visits.

          9. Patients must provide written informed consent.

             -

        Exclusion Criteria:

          1. Patients who are candidates for either partial or total bladder resection, unless
             either medically contraindicated or who have refused surgery.

          2. Patients with a tumor in a diverticulum, in the prostatic urethra, or covering the
             ureteral orifice.

          3. Patients who have received cytotoxic drugs, systemic corticosteroids or any
             investigational drug for any indication within 4 weeks of the start of protocol
             treatment.

          4. Patients who have received any intravesical therapy other than surgical resection
             within 8 weeks prior to the start of protocol treatment.

          5. Patients who have received radiation therapy for bladder cancer at any time or for any
             condition within 4 months prior to the start of protocol treatment.

          6. Patients who have active infections, including urinary tract infections, whether
             viral, bacterial or fungal and requiring therapy.

          7. Patients who are receiving coumadin.

          8. Patients who have had to discontinue a past course of BCG due to toxicity.

          9. Patients who are having urinary tract signs or symptoms from recent urinary tract
             procedures or manipulations, such as biopsies or catheterizations.

         10. Patients who are known to be HIV positive.

         11. Females who are pregnant or breast feeding.

         12. Presence of any medical, psychological or social condition or situation which may, in
             the investigator's opinion, make it difficult for the patient to tolerate study
             medication or comply with study procedures and other requirements. This includes but
             is not limited to active infections, poorly controlled diabetes, uncontrolled cardiac
             arrhythmias, angina pectoris, or hypertension.

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ami Sidi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wolfson Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarel Halachmi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bnai-Zion Medical Center, Haifa, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ilan Leibovitch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meir Medical Center, Kfar-Saba, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ofer Gofrit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Ein Karem Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amnon Zisman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assaf Harofe Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abraham Stein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carmel Hospital,Haifa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haim Matzkin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel Aviv Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bnai Zion MC</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Karem Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir MC</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf Harofe Medical Center</name>
      <address>
        <city>Zerifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.biocancell.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 29, 2013</study_first_submitted>
  <study_first_submitted_qc>June 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2013</study_first_posted>
  <last_update_submitted>March 8, 2019</last_update_submitted>
  <last_update_submitted_qc>March 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inodiftagene vixteplasmid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BCG Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

